Takeda Seeks Diabetes, Other Lifestyle Drugs To Supplant Actos Loss
This article was originally published in PharmAsia News
Takeda Pharmaceuticals says it is looking to drugs for diabetes and other lifestyle diseases to drive sales to replace losses due to generic competition for its Actos (pioglitazone) diabetes drug
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.